Poster presented—Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort

Written By Lara Wilson

Aribi, A., et al. European Hematology Association 2024. June 13–16, 2024

Lara Wilson
Previous

Publication—Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
Next

A first-in-human phase 1 study of IO-202 (anti-LILRB4 mAb) in acute myeloid leukemia (AML) with monocytic differentiation and chronic myelomonocytic leukemia (CMML) patients